Şizofrenide fötalite
3201 Kere Okundu

Foetality in schizophrenia
Elif Mutlu, Mehmet Emin Ceylan, Agah Aydın
Bakırköy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, İstanbul, Turkey
E-mail: elifmutlu@yahoo.com
Objective: The aim of this study was to evaluate common morphological and neurological features of schizophrenia from an ontogenetic
perspective and to propose a new conceptual approach to schizophrenia, in which early foetal marks persist without diminishing in
comparison to other people.
Material and Methods: Fifty patients diagnosed with schizophrenia from the Bakırköy Research and Training Hospital for Psychiatry,
Neurology and Neurosurgery were chosen for the study group. The control group consists of fifty healthy male subjects. The ages of
all subjects varied between 18 and 65. All of the subjects were informed about the study and their written consents were obtained.
Sociodemographic data of all subjects were recorded and the Waldrop Minor Physical Anomalies Scale, the NES ( neurological evaluation
scale), and the Edinburgh Handedness Inventory were applied.
Results: We found significantly higher scores among schizophrenic patients in comparison to healthy subjects both in the NES total and
all four sub-categories of the scale. The minor physical anomalies scores, head circumference, and hypertelorism were significantly higher
in the schizophrenic group. In addition, for hand-eye dominancy, we observed more tendency to be crosswise.
Conclusion: Some characteristics of schizophrenia such as hypertelorism, large head circumference, high palate, thin muscle and
bone structure, primitive reflexes, mental and behavioral characteristics could be evaluated as a separate ontogenetic entity.Evaluating
schizophrenia within the context of a neurodevelopmental hypothesis, as an evolutionary process, in which foetal traits persist, would
contribute to our understanding of the disorder’s ambigous nature and phenomenology.
Key words: Schizophrenia, foetality, ontogenesis
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S171